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Abstract Most interactions of calmodulin (CaM) with its target
proteins are Ca2+-dependent, but a few Ca2+-independent CaM-
target protein interactions have been identified. One example is
the inducible isoform of nitric oxide synthase (iNOS) expressed
in macrophages. We describe here the characterization of the
Ca2+-independent interaction between CaM and a synthetic
peptide corresponding to the CaM-binding domain of murine
macrophage iNOS using circular dichroism (CD) spectroscopy.
The CD spectrum of free iNOS peptide indicated a L-sheet
conformation. The interaction of iNOS peptide with apo-CaM in
the absence of Ca2+ resulted in the peptide acquiring a type II L-
turn structure. This is in contrast to the situation in the presence
of Ca2+ in which case the peptide acquired an K-helical
conformation upon interaction with CaM, i.e. similar to the
Ca2+-dependent interactions of CaM with numerous targets such
as myosin light chain kinase (MLCK). Consistent with this
similar structural change, iNOS peptide inhibited the Ca2+-
CaM-dependent activation of smooth muscle MLCK by
competing with MLCK for binding to Ca2+-CaM. The Kd of
Ca2+-CaM for iNOS peptide was calculated from competition
assays to be 0.3 nM. These results indicate that the structure of
the CaM-binding domain of iNOS is quite different when bound
to apo-CaM than Ca2+-CaM.
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1. Introduction
Calmodulin (CaM), the ubiquitous Ca2-binding regulatory
protein, binds to and activates more than 40 di¡erent target
proteins, including protein kinases, protein phosphatase 2B
(calcineurin), nitric oxide synthases, cyclic nucleotide phos-
phodiesterase, ion channels, and myo¢lament-associated pro-
teins such as caldesmon and calponin (for reviews, see [1^4]).
In the absence or presence of four Ca2 ions, CaM adopts a
dumbbell-shaped structure with two lobes connected by a 26-
residue central linker region [5^7]. Each lobe of CaM contains
two helix-loop-helix Ca2-binding motifs connected by a small
L-sheet. Although the central linker region of Ca2-CaM is an
K-helix in the X-ray structure [5], nuclear magnetic resonance
(NMR) relaxation measurements indicated that the central
part of the linker region is unstructured in solution [8]. The
majority of hydrophobic residues in apo-CaM are buried in-
side the protein [6,7]. Upon binding four Ca2 ions, CaM
experiences signi¢cant movements among the K-helices in
each lobe and the interhelix angle changes signi¢cantly. As
a result, Ca2-CaM exposes two Met-rich hydrophobic
patches, one on each lobe of CaM, which are involved in
target protein binding [5]. The CaM-binding domains in tar-
get proteins usually comprise a stretch of V20 amino acid
residues which have the potential to form a basic amphipathic
K-helix [3,9]. The high resolution structure of Ca2-CaM-tar-
get peptide complexes revealed that the peptides bind to Ca2-
CaM as K-helices and the side-chain hydrophobic interactions
between peptide and Ca2-CaM constitute the dominant force
in the binding [10^12].
It is generally believed that the £exible central linker region
and the two Met-rich hydrophobic patches are important fea-
tures for CaM’s versatility. The £exible central linker region
can unwind to di¡erent extents to accommodate various tar-
get proteins, while the Met residues provide a highly adjust-
able hydrophobic surface for distinct target protein binding
due to the intrinsic £exibility of the Met residues and the high
polarizability of sulfur atoms [13].
While most CaM-target protein interactions are Ca2-de-
pendent, a few examples of Ca2-independent binding of
CaM to speci¢c proteins have been discovered. For instance,
one of the isoforms of nitric oxide synthase (NOS) binds CaM
in a Ca2-independent manner. NOS catalyzes the synthesis of
the messenger molecule NO from L-arginine [14,15]. NO has
many physiological and pathological e¡ects including smooth
muscle relaxation, neurotransmission and cytotoxicity. NOS
can be divided into constitutive and inducible forms (cNOS
and iNOS, respectively). Neuronal (type I) and endothelial
(type III) cNOS are activated by CaM in response to ago-
nist-induced increases in intracellular free Ca2 concentration,
i.e. they behave like classical Ca2-CaM-regulated enzymes.
In contrast, macrophage (type II) iNOS, whose expression is
induced by cytokines and bacterial endotoxin, remains active
independent of Ca2 concentration; furthermore, CaM binds
tightly to iNos even in the absence of Ca2 [16]. Both cNOS
and iNOS have similar structural features including a cyto-
chrome P-450-like heme protein domain and a cytochrome P-
450 reductase-like £avoprotein domain connected by a CaM-
binding domain [17]. The CaM-binding domains of cNOS and
iNOS were identi¢ed by sequence inspection and predicted
secondary structure (basic amphipathic K-helix) and corre-
spond to residues 725^754 of rat brain cNOS [18,19] and
residues 504^532 of murine macrophage iNOS [20].
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A useful approach to studying the mechanism of activation
of target enzymes by CaM involves the use of synthetic pep-
tides corresponding to the CaM-binding domains of the target
proteins. To date, relatively little is known about CaM-target
protein interactions that occur independent of Ca2. We re-
port here the characterization of the interaction between a 27-
residue synthetic peptide corresponding to the CaM-binding
domain of iNOS and apo-CaM or Ca2-CaM.
2. Materials and methods
2.1. Materials
[Q-32P]ATP (s 5000 Ci/mmol) was purchased from Amersham
Corp. (Oakville, Ontario, Canada). CaM was puri¢ed from bovine
brain [21] or was expressed in E. coli and puri¢ed as described by
Zhang and Vogel [22]. Myosin light chain kinase (MLCK) was puri-
¢ed from chicken gizzard smooth muscle [23]. iNOS peptide was syn-
thesized by the Protein and DNA Synthesis Facility at Queen’s Uni-
versity, Kingston, Ontario, Canada. MLC11ÿ23 peptide, used as
substrate for MLCK, was synthesized by the Peptide Synthesis Core
Facility at the University of Calgary, Calgary, Alberta, Canada. The
purity of peptides was con¢rmed by analytical high performance
liquid chromatography, amino acid analysis and mass spectrometry.
The sequences of these peptides are (i) MLC11ÿ23 : KKRPQRATSNV-
FA, corresponding to residues 11^23 of the 20 kDa light chain sub-
unit of chicken gizzard smooth muscle myosin II, Ser-19 being the
site of phosphorylation by MLCK [24]; (ii) iNOS peptide:
RRREIRFRVLVKVVFFASMLMRKVMAS, corresponding to the
CaM-binding domain of murine macrophage iNOS (residues 503^
529) [25,26].
2.2. CD spectroscopy
CD spectra were acquired on a Jasco J-715 spectropolarimeter in
the Department of Chemistry, University of Calgary, Calgary, Alber-
ta, Canada. All experiments were performed at room temperature
(22‡C) using a 1 mm path length cylindrical quartz cuvette. The pa-
rameters used were as follows: 0.2 nm step resolution, 50 nm/min
speed, 2 s response time, 1 nm bandwidth. The sensitivity is 20 mdeg
and spectra were averaged from 10 scans. The CaM or iNOS peptide
concentration was 10 WM in 10 mM Tris-HCl, pH 7.2, with 2 mM
CaCl2 or 2 mM EDTA, and a total sample volume of 200 Wl. The
background signals due to the bu¡er were subtracted from each spec-
trum, which was then smoothed and converted to molar ellipticity
using Jasco software. The CD spectra were reported either as molar
ellipticity or as mean residue molar ellipticity.
2.3. MLCK assays
MLCK activity was measured at 30‡C under the following condi-
tions: 20 nM Tris-HCl, pH 7.5, 60 mM KCl, 4 mM MgCl2, 0.2 mM
CaCl2, 0.2 mM [Q-32P]ATP (V300 cpm/pmol), 0.1 mM MLC11ÿ23,
0^400 nM CaM, 10 nM MLCK and varying concentrations of
iNOS peptide. reactions (30 Wl) were started by addition of ATP
and quenched after 5 min by spotting 20 Wl onto P81 phosphocellulose
paper squares (Whatman) which were washed and counted as previ-
ously described [27]. Phosphate incorporation into MLC11ÿ23 was
shown to be linear for at least 5 min. Maximal MLCK activity ob-
served at 400 nM CaM was 0.44 þ 0.16 Wmol Pi incorporated/min mg
MLCK (mean þ S.D. of 28 independent measurements, each carried
out in triplicate). Basal MLCK activity in the absence of CaM was
0.08 þ 0.03 Wmol Pi incorporated/min mg MLCK (mean þ S.D. of
30 independent measurements, each carried out in triplicate).
The dissociation constant (Kd) of CaM for iNOS peptide was cal-
culated from the midpoints of the activation curves of MLCK by
CaM in the absence and presence of a known concentration of pep-
tide using the following equation [28]:
Kd  Pt K3CaMKCaM3K
where [Pt] is the total concentration of peptide added, K and [CaM]
are the concentrations of CaM required to reach half-maximal acti-
vation in the absence and presence of peptide, respectively.
3. Results
3.1. CD spectroscopy
The structure of the free iNOS peptide was examined ini-
tially by CD spectroscopy, and the e¡ects of increasing con-
centrations of tri£uoroethanol (TFE) on the CD spectrum
were analyzed. TFE induces an K-helical conformation in
peptides that have a tendency to form this structure, which
is the case for many CaM-binding domain peptides [1,3]. The
CD spectrum of iNOS peptide in aqueous solution (no TFE)
is indicative of a L-sheet conformation in equilibrium with a
random coil conformation (Fig. 1A). TFE titration of the
iNOS peptide in aqueous solution induced an initial increase
followed by a decrease of the ellipticity at 222 nm which was
incomplete even at a TFE concentration of 60% (Fig. 1B).
The CD spectrum of iNOS peptide in 60% TFE is still similar
to a L-sheet conformation with a positive band around 197
nm and a negative band around 220 nm (Fig. 1A). This struc-
ture contrasts with classical CaM-binding domain peptides
which display an K-helical conformation, particularly in the
presence of TFE [1,3,29].
Since CaM binds tightly to iNOS even in the absence of
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Fig. 1. E¡ect of tri£uoroethanol on the CD spectrum of iNOS pep-
tide. A: The CD spectrum of iNOS peptide alone was recorded in
aqueous solution (thick line) or in 60% TFE (dashed line). B: The
e¡ect of increasing [TFE] on mean residue ellipticity at 222 nm; val-
ues were determined from CD spectra of iNOS peptide alone re-
corded at the indicated concentrations of TFE.
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Ca2 [16], we studied the apo-CaM-iNOS peptide interaction
by CD spectroscopy. As shown in Fig. 2A, addition of the
iNOS peptide increased the molar ellipticity of apo-CaM at
208 nm and decreased that at 222 nm. The resulting di¡erence
spectrum (Fig. 2B) shows a typical type II L-turn CD spec-
trum with a positive band between 200^210 nm and a weak
negative band between 220^230 nm [30,31] ; other L-sheet and
L-hairpin structures may, however, result in similar spectra so
that such structures cannot be totally excluded [30,31]. Since
apo-CaM usually maintains its secondary structure in the
apo-CaM-peptide complex [32], the di¡erence CD spectrum
can be assigned to the bound peptide. As indicated earlier,
the free iNOS peptide in aqueous solution probably adopts a
L-sheet conformation in equilibrium with a random coil con-
formation. There is a clear conformational change induced in
the iNOS peptide when it binds to apo-CaM (Fig. 2B) and,
most signi¢cantly, the peptide does not acquire an K-helical
conformation as a result of this Ca2-independent interaction.
The secondary structure changes occurring upon formation
of the Ca2-CaM-iNOS peptide complex were also examined
by CD spectroscopy (Fig. 3). Addition of iNOS peptide to
CaM in the presence of Ca2 decreased the molar ellipticity
at both 208 nm and 222 nm. Since Ca2-CaM usually does
not gain any secondary structure upon interaction with a tar-
get peptide [10,11], this ellipticity change can be attributed to
the iNOS peptide which binds to Ca2-CaM in an K-helical
conformation. The structural changes occurring in the iNOS
peptide as it binds to apo-CaM and Ca2-CaM are, therefore,
quite distinct.
3.2. E¡ect of iNOS peptide on Ca2+-CaM-dependent activation
of MLCK
The a⁄nity of Ca2-CaM for iNOS peptide was determined
by a competition assay with MLCK, a target enzyme which is
activated by CaM in a Ca2-dependent manner [33]. Fig. 4
shows the e¡ect of increasing concentrations of iNOS peptide
on MLCK activity at a ¢xed concentration of CaM (100 nM)
su⁄cient for maximal activation of the kinase. Half-maximal
inhibition was observed at V60 nM iNOS peptide. Inhibition
of MLCK by 60 nM iNOS peptide could be overcome by
increasing the CaM concentration (Fig. 5). A higher concen-
tration of iNOS peptide (1 WM) completely prevented activa-
tion of MLCK over the range 0^400 nM CaM (Fig. 5). The
Kd value of Ca2-CaM for iNOS peptide was determined
from the CaM activation curves in the absence and presence
of 60 nM iNOS peptide to be 0.3 nM.
4. Discussion
Previous studies of synthetic peptides corresponding to res-
idues 499^532 and 504^532 of murine macrophage iNOS in-
dicated this region to be the CaM-binding domain [20]. We
have con¢rmed this conclusion by CD spectroscopy of a syn-
thetic peptide corresponding to residues 503^529 of iNOS and
by the demonstration that this peptide inhibits the Ca2-
CaM-dependent activation of smooth muscle MLCK in a
manner which is overcome by Ca2-CaM. Competition assays
with MLCK enabled determination of the Kd of Ca2-CaM
for iNOS peptide to be 0.3 nM, comparable to values reported
previously using similar iNOS peptides but di¡erent methods:
6 0.1 nM [34], 6 1.0 nM [20], 1.5 nM [35] and 3.3 nM [36].
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Fig. 3. Far-UV CD spectra of iNOS peptide, Ca2-CaM and the
Ca2-CaM-iNOS peptide complex. CD spectra were recorded as de-
scribed in Section 2 for iNOS peptide alone (dash-dot line), Ca2-
CaM alone (thick line) or an equimolar mixture of iNOS peptide
and Ca2-CaM (dashed line).
Fig. 2. A. Far-UV CD spectra of iNOS peptide, apo-CaM and the
apo-CaM-iNOS peptide complex. CD spectra were recorded as de-
scribed in Section 2 for iNOS peptide alone (dash-dot line), apo-
CaM alone (thick line) or an equimolar mixture of iNOS peptide
and apo-CaM (dashed line). B: Far-UV CD spectra of iNOS pep-
tide (dash-dot line) and the di¡erence spectrum between apo-CaM-
iNOS peptide complex and apo-CaM (dotted line).
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The peptide most closely related to the one used in this study
was that of Zoche et al. [34] which lacked the C-terminal Ser.
We have utilized CD spectroscopy to analyze the interac-
tion between the CaM-binding domain of iNOS and either
Ca2-CaM or apo-CaM. Our results show that the iNOS
peptide binds to Ca2-CaM in an K-helical conformation.
This is a normal binding mode for the CaM-binding domains
of CaM target proteins [1^4]. Since the CaM-binding domain
peptide of MLCK also binds to Ca2-CaM with an K-helical
conformation [10,11], iNOS peptide may compete with
MLCK binding to Ca2-CaM, and this is supported by the
demonstration that iNOS peptide inhibits MLCK and inhib-
ition is overcome by increasing [CaM]. A similar iNOS pep-
tide inhibited the Ca2-CaM-activated erythrocyte plasma
membrane Ca2 pump [20]. The iNOS CaM-binding domain
retains the three aromatic or long-chain hydrophobic side
chains that form key contacts with CaM in the Ca2-CaM-
MLCK peptide complex (Fig. 6). Although hydrophobic res-
idues appear to be more important than charged residues in
binding to CaM, basic residues are invariably found in CaM-
binding domains and many of them contribute to CaM bind-
ing via electrostatic interactions between basic residues in the
CaM-binding protein and acidic regions in CaM. All seven
basic residues in the CaM-binding domain of MLCK make
salt bridges with CaM [11]. Although only one of these is
conserved in the iNOS CaM-binding domain (as an Arg for
Lys substitution; shaded in Fig. 6), the iNOS peptide contains
eight basic residues and only one acidic residue for a net
charge of +7 (Fig. 6). Interestingly, iNOS peptide is predom-
inantly in a L-sheet conformation in aqueous solution (Fig. 1)
and it becomes K-helical when bound to Ca2-CaM (Fig. 3),
i.e. a L-sheet to K-helix transition is induced in iNOS peptide
by Ca2-CaM binding. In contrast, for cNOS the CaM-bind-
ing domain has a random structure in aqueous solution, but it
forms an K-helix in TFE or upon binding to Ca2-CaM
[37,38]. In contrast to iNOS (see below) the cNOS peptide
also does not bind to apo-CaM, showing that the CaM-bind-
ing domains of iNOS and cNOS have markedly distinct con-
formational properties, which are related to the di¡erent acti-
vation properties of both enzymes.
CD spectroscopy also indicated that the iNOS peptide
binds to apo-CaM (Fig. 2), which is consistent with previous
¢ndings that the iNOS peptide interacts with CaM even in the
presence of EDTA [34,39]. Most interestingly, the iNOS pep-
tide binds to apo-CaM in a type II L-turn conformation (Fig.
2B), i.e. quite di¡erent from the K-helical conformation the
peptide acquires upon binding to Ca2-CaM. This conforma-
tion is also quite di¡erent from the L-sheet conformation
adopted by iNOS peptide in aqueous solution (Fig. 2B). A
recent study utilizing CD and NMR spectroscopy showed that
a shorter, modi¢ed iNOS peptide analog (KRREIPLKVLV-
KAVLFACMLMRK) assumes a nascent K-helical structure
in aqueous solution and binds to both apo-CaM and Ca2-
CaM in an K-helical conformation [36]. This peptide was used
because of its greater solubility and since longer iNOS pep-
tides caused formation of large aggregates when added to
CaM, leading to precipitation of the peptide-CaM complex
[20,39]. The Agadir secondary structure prediction program
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Fig. 4. iNOS peptide-mediated inhibition of Ca2-CaM-dependent
MLCK. MLCK activity was measured in the presence of the indi-
cated concentrations of iNOS peptide. 100% activity refers to the
kinase activity in the absence of iNOS peptide.
Fig. 5. Activation of MLCK by Ca2-CaM in the absence and pres-
ence of iNOS peptide. MLCK activity was measured in the presence
of the indicated concentrations of CaM and in the absence (a) or
presence of 60 nM (b) or 1 WM (S) iNOS peptide. The Kd for
iNOS peptide binding to Ca2-CaM was calculated using the fol-
lowing values: K = 26.7 nM (calculated from the CaM activation
curve in the absence of iNOS peptide), [CaM] = 86 nM (calculated
from the CaM activation curve in the presence of 60 nM iNOS pep-
tide) and [Pt] = 60 nM.
Fig. 6. Comparison of the amino acid sequences of the CaM-bind-
ing domains of iNOS and MLCK. The iNOS peptide sequence cor-
responds to residues 503^529 of murine macrophage iNOS [25,26]
and the MLCK sequence to residues 794^820 of chicken gizzard
MLCK [48]. Boxed residues indicate the three hydrophobic amino
acids that have been implicated in the binding of MLCK to CaM
and the corresponding conserved residues in the CaM-binding do-
main of iNOS. Shaded residues indicate the location of the con-
served positive charge.
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which has been speci¢cally developed for peptides rather than
proteins (available on the web site of The European Molec-
ular Biology Laboratory) [40] predicted the modi¢ed iNOS
peptide analog of Matsubara et al. [36] to have V12% K-
helical content while the unmodi¢ed iNOS peptide used in
this study is predicted to have an K-helical content of only
V4%. Thus, the substitutions in the modi¢ed iNOS peptide
likely change its structural properties; hence, caution must be
exercised when extending the results obtained with the modi-
¢ed peptide to the native protein. We observed no solubility
or aggregation problems with the native iNOS peptide at the
concentrations used in these studies, but were unable to carry
out near-UV CD spectroscopy, infrared or NMR spectros-
copy studies due to such problems at the higher concentra-
tions required to successfully apply the latter techniques.
The region outside the putative CaM-binding domain of
iNOS (residues 501^532) has been implicated in the Ca2-in-
dependent binding of iNOS to CaM [35,41]. Further studies
with longer peptides or intact protein are required to elucidate
the detailed interaction between CaM and iNOS. Neverthe-
less, our studies are insightful in understanding the interaction
between CaM and a target protein that binds to CaM in the
absence and presence of Ca2. Other such target enzymes
include a cyclic nucleotide phosphodiesterase isoenzyme,
PDE1A1 [42], the Q subunit of glycogen phosphorylase kinase
[43] and adenylyl cyclase of Bordetella pertussis [44].
To date, the only peptide that binds to apo-CaM and has
been well characterized is the CaM-binding domain of neuro-
modulin. The neuromodulin peptide binds to apo-CaM as an
K-helix, as demonstrated by NMR spectroscopy [45,46] and
CD spectroscopy [47]. It has also been shown that the general
secondary structure of apo-CaM is maintained in this complex
[32]. Thus, our study with iNOS peptide presents a novel
peptide-apo-CaM interaction in which a type II L-turn rather
than an K-helix is formed.
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